Strong Market Position & Advantage:
Broad adoption across large pharma and recognition as a leader in physics‑based discovery software indicate a durable competitive edge, reinforced by flagship tools like Glide and FEP+ with peer‑reviewed validation. Penetration across all top global pharma and sticky, long‑tenure accounts suggest standard‑tool status in discovery teams.
Strong Revenue Growth:
Recent results show higher software revenue and total revenue growth in 2025, with guidance pointing to continued expansion in software ACV in 2026. Management frames software as the scaled growth engine while hosted deployments rise.
Strategic Partnerships:
Large, multi‑year collaborations with major pharmas and long‑running technical work with NVIDIA support pipeline upside and platform performance. Deal structures with upfronts, milestones, and potential royalties diversify growth levers.
